The Molecular Epidemiological Study of HCV Subtypes among Intravenous Drug Users and Non-Injection Drug Users in China.
More than half of intravenous drug users (IDUs) in China suffer from the Hepatitis C virus (HCV). The virus is also more prevalent in non-injection drug users (NIDUs) than in the general population. However, not much is known about HCV subtype distribution in these populations.Our research team cond...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4605846?pdf=render |
| _version_ | 1830135756664864768 |
|---|---|
| author | Jun Tao Jun Liang Hui Zhang Lijian Pei Han-Zhu Qian Matthew C Chambers Yan Jiang Yao Xiao |
| author_facet | Jun Tao Jun Liang Hui Zhang Lijian Pei Han-Zhu Qian Matthew C Chambers Yan Jiang Yao Xiao |
| author_sort | Jun Tao |
| collection | DOAJ |
| description | More than half of intravenous drug users (IDUs) in China suffer from the Hepatitis C virus (HCV). The virus is also more prevalent in non-injection drug users (NIDUs) than in the general population. However, not much is known about HCV subtype distribution in these populations.Our research team conducted a cross-sectional study in four provinces in China. We sampled 825 IDUs and 244 NIDUs (1162 total), genotyped each DU's virus, and performed a phylogenetic analysis to differentiate HCV subtypes.Nucleic acid testing (NAT) determined that 82% percent (952/1162) of samples were HCV positive; we subtyped 90% (859/952) of these. We found multiple HCV subtypes: 3b (249, 29.0%), 3a (225, 26.2%), 6a (156, 18.2%), 1b (137, 15.9%), 6n (50, 5.9%), 1a (27, 3.1%), and 2a (15, 1.7%). An analysis of subtype distributions adjusted for province found statistically significant differences between HCV subtypes in IDUs and NIDUs.HCV subtypes 3b, 3a, 6a, and 1b were the most common in our study, together accounting for 89% of infections. The subtype distribution differences we found between IDUs and NIDUs suggested that sharing syringes was not the most likely pathway for HCV transmission in NIDUs. However, further studies are needed to elucidate how NIDUs were infected. |
| first_indexed | 2024-12-17T07:38:35Z |
| format | Article |
| id | doaj.art-0e02da09a43d477c93c2f51205deda83 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-17T07:38:35Z |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-0e02da09a43d477c93c2f51205deda832022-12-21T21:58:13ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-011010e014026310.1371/journal.pone.0140263The Molecular Epidemiological Study of HCV Subtypes among Intravenous Drug Users and Non-Injection Drug Users in China.Jun TaoJun LiangHui ZhangLijian PeiHan-Zhu QianMatthew C ChambersYan JiangYao XiaoMore than half of intravenous drug users (IDUs) in China suffer from the Hepatitis C virus (HCV). The virus is also more prevalent in non-injection drug users (NIDUs) than in the general population. However, not much is known about HCV subtype distribution in these populations.Our research team conducted a cross-sectional study in four provinces in China. We sampled 825 IDUs and 244 NIDUs (1162 total), genotyped each DU's virus, and performed a phylogenetic analysis to differentiate HCV subtypes.Nucleic acid testing (NAT) determined that 82% percent (952/1162) of samples were HCV positive; we subtyped 90% (859/952) of these. We found multiple HCV subtypes: 3b (249, 29.0%), 3a (225, 26.2%), 6a (156, 18.2%), 1b (137, 15.9%), 6n (50, 5.9%), 1a (27, 3.1%), and 2a (15, 1.7%). An analysis of subtype distributions adjusted for province found statistically significant differences between HCV subtypes in IDUs and NIDUs.HCV subtypes 3b, 3a, 6a, and 1b were the most common in our study, together accounting for 89% of infections. The subtype distribution differences we found between IDUs and NIDUs suggested that sharing syringes was not the most likely pathway for HCV transmission in NIDUs. However, further studies are needed to elucidate how NIDUs were infected.http://europepmc.org/articles/PMC4605846?pdf=render |
| spellingShingle | Jun Tao Jun Liang Hui Zhang Lijian Pei Han-Zhu Qian Matthew C Chambers Yan Jiang Yao Xiao The Molecular Epidemiological Study of HCV Subtypes among Intravenous Drug Users and Non-Injection Drug Users in China. PLoS ONE |
| title | The Molecular Epidemiological Study of HCV Subtypes among Intravenous Drug Users and Non-Injection Drug Users in China. |
| title_full | The Molecular Epidemiological Study of HCV Subtypes among Intravenous Drug Users and Non-Injection Drug Users in China. |
| title_fullStr | The Molecular Epidemiological Study of HCV Subtypes among Intravenous Drug Users and Non-Injection Drug Users in China. |
| title_full_unstemmed | The Molecular Epidemiological Study of HCV Subtypes among Intravenous Drug Users and Non-Injection Drug Users in China. |
| title_short | The Molecular Epidemiological Study of HCV Subtypes among Intravenous Drug Users and Non-Injection Drug Users in China. |
| title_sort | molecular epidemiological study of hcv subtypes among intravenous drug users and non injection drug users in china |
| url | http://europepmc.org/articles/PMC4605846?pdf=render |
| work_keys_str_mv | AT juntao themolecularepidemiologicalstudyofhcvsubtypesamongintravenousdrugusersandnoninjectiondrugusersinchina AT junliang themolecularepidemiologicalstudyofhcvsubtypesamongintravenousdrugusersandnoninjectiondrugusersinchina AT huizhang themolecularepidemiologicalstudyofhcvsubtypesamongintravenousdrugusersandnoninjectiondrugusersinchina AT lijianpei themolecularepidemiologicalstudyofhcvsubtypesamongintravenousdrugusersandnoninjectiondrugusersinchina AT hanzhuqian themolecularepidemiologicalstudyofhcvsubtypesamongintravenousdrugusersandnoninjectiondrugusersinchina AT matthewcchambers themolecularepidemiologicalstudyofhcvsubtypesamongintravenousdrugusersandnoninjectiondrugusersinchina AT yanjiang themolecularepidemiologicalstudyofhcvsubtypesamongintravenousdrugusersandnoninjectiondrugusersinchina AT yaoxiao themolecularepidemiologicalstudyofhcvsubtypesamongintravenousdrugusersandnoninjectiondrugusersinchina AT juntao molecularepidemiologicalstudyofhcvsubtypesamongintravenousdrugusersandnoninjectiondrugusersinchina AT junliang molecularepidemiologicalstudyofhcvsubtypesamongintravenousdrugusersandnoninjectiondrugusersinchina AT huizhang molecularepidemiologicalstudyofhcvsubtypesamongintravenousdrugusersandnoninjectiondrugusersinchina AT lijianpei molecularepidemiologicalstudyofhcvsubtypesamongintravenousdrugusersandnoninjectiondrugusersinchina AT hanzhuqian molecularepidemiologicalstudyofhcvsubtypesamongintravenousdrugusersandnoninjectiondrugusersinchina AT matthewcchambers molecularepidemiologicalstudyofhcvsubtypesamongintravenousdrugusersandnoninjectiondrugusersinchina AT yanjiang molecularepidemiologicalstudyofhcvsubtypesamongintravenousdrugusersandnoninjectiondrugusersinchina AT yaoxiao molecularepidemiologicalstudyofhcvsubtypesamongintravenousdrugusersandnoninjectiondrugusersinchina |